S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
CVE:TAK

Takeda Pharmaceutical Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume143,897 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Medicinal and Botanical Manufacturing
Sub-Industry
N/A
CIK
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Takeda Pharmaceutical (CVE:TAK) Frequently Asked Questions

What stocks does MarketBeat like better than Takeda Pharmaceutical?

Wall Street analysts have given Takeda Pharmaceutical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Takeda Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:
  • Gilles Dessureau, Interim President
  • Gregory Donald Hayes, Interim Chief Financial Officer, Corporate Secretary
  • Peter Bures, Director
  • Dennis Gordon Fentie, Director
  • Janet Lee-Sheriff, Director
  • Lori Walton, Director
  • C.F. Wasser III, Director

Who are some of Takeda Pharmaceutical's key competitors?

Some companies that are related to Takeda Pharmaceutical include Tilray (TLRY), Theseus Pharmaceuticals (THRX), Advantis (ADVT), High Tide (HITI) and Novus Energy (NVS).
View all of TAK's competitors
.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Pure Gold Mining (PGM), Valhi (VHI) and Fission Uranium (FCUUF).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the Canadian Venture Exchange (CVE) under the ticker symbol "TAK."

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How many employees does Takeda Pharmaceutical have?

Takeda Pharmaceutical employs 2,021 workers across the globe.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takugold.com.

Where are Takeda Pharmaceutical's headquarters?

Takeda Pharmaceutical is headquartered at 409 Granville St Suite 608, VANCOUVER, BC V6C 1T2, Canada.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 409 Granville St Suite 608, VANCOUVER, BC V6C 1T2, Canada. The company can be reached via phone at +1-604-6420115.


This page was last updated on 10/22/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.